TRILUMINATE update: TEER with Abbott's TriClip device still safe, effective after 3 years
TEER with TriClip reduced TR to moderate or less in 79% of patients, with sustained benefits including TR reduction and QOL improvements at three years. The proportion of patients with NYHA class III or IV dropped from 76% to 19%. The safety profile remains favorable, though the impact on mortality or hospitalization for heart failure is unclear.
Reference News
TRILUMINATE update: TEER with Abbott's TriClip device still safe, effective after 3 years
TEER with TriClip reduced TR to moderate or less in 79% of patients, with sustained benefits including TR reduction and QOL improvements at three years. The proportion of patients with NYHA class III or IV dropped from 76% to 19%. The safety profile remains favorable, though the impact on mortality or hospitalization for heart failure is unclear.